Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus

E M C Sella, E I Sato, W A Leite, J A Oliveira Filho, A Barbieri

Objective: To evaluate the prevalence of myocardial perfusion abnormalities and the possible association between myocardial perfusion defects and traditional coronary artery disease (CAD) risk factors as well as systemic lupus erythematosus (SLE) related risk factors.

Patients and methods: Female patients with SLE, disease duration >5 years, age 18–55 years, who had used steroids for at least one year were enrolled. Traditional CAD risk factors evaluated were arterial hypertension, diabetes mellitus, dyslipidaemia, postmenopausal status, smoking, obesity, and premature family CAD profile. Myocardial perfusion scintigraphy was evaluated by single photon emission computed tomography with technetium 99m-sestamibi at rest and after dipyridamole induced stress.

Results: Eight two female patients with SLE without angina pectoris with mean (SD) age 37 (10) years, disease duration 127 (57) months, SLE Disease Activity Index (SLEDAI) score 6 (5), and SLICC/ACR-DI score 2 (2) were evaluated. Myocardial perfusion abnormalities were found in 23 patients (28%). The mean (SD) number of CAD risk factors was 2.2 (1.6). There was a significant positive correlation between age and number of CAD risk factors. Lower high density lipoprotein (HDL) cholesterol level showed a significant association with abnormal scintigraphy. Logistic regression analysis showed that lower HDL cholesterol level and diabetes mellitus were associated with myocardial perfusion abnormalities. Current vasculitis was also associated with abnormal scintigraphy.

Conclusions: Lower HDL cholesterol level and diabetes mellitus have a significant influence on abnormal myocardial perfusion results found in asymptomatic patients with SLE. Current vasculitis was associated with abnormal myocardial scintigraphy. These data suggest that abnormal myocardial scintigraphy may be related to subclinical atherosclerosis.

The survival of patients with systemic lupus erythematosus (SLE) has improved in the past three decades. Despite the improved survival patients with SLE still die at a rate that is three times greater than that of the general population.1 Many studies have shown that premature atherosclerosis is one of the major causes of morbidity and mortality in these patients.2–4

Angina pectoris has been reported to occur in up to 12% of patients,5–7 acute myocardial infarction (MI) in up to 16%,5,57–10 and sudden death in up to 8%.8,10–12 Manzi et al reported a 52 times higher risk for cardiovascular disease in young women with SLE than in controls matched for age and sex in the Framingham Study.7 The rate of acute MI as the primary cause of death in SLE has been reported to be up to 36% in various studies.2,6,10–16 Esaadle et al showed that the risk for all relevant cardiovascular outcomes was higher in patients with SLE even after accounting for all traditional Framingham risk factors.17

In addition to the traditional coronary artery disease (CAD) risk factors, inflammatory, immunological, metabolic, and haemostatic factors have been described as independent risk factors for premature CAD in patients with SLE. Homocysteine levels18–19 and antiphospholipid antibodies20–21 are some of these factors. Other potential mechanisms for coronary ischaemia, such as vasculitis,22–23 immune complex deposition,24 microvascular disease,25 intracoronary thrombus,25 and coronary aneurysms,26–28 may also contribute to acute coronary events. Longer duration of SLE, older age at SLE diagnosis, and steroid treatment are also SLE disease related factors that seem to contribute to CAD.25,28

There is no consensus about the best diagnostic method for subclinical CAD in patients with SLE, but the ability of vascular imaging techniques to measure atherosclerosis in subclinical stages may allow better risk stratification.10,32

The objective of this study was to evaluate the prevalence of myocardial perfusion abnormalities in asymptomatic female patients with SLE. The secondary objectives were to evaluate the possible association between myocardial perfusion defects and traditional CAD risk factors, age, and the number of American College of Rheumatology (ACR) criteria, vasculitis history, presence of anticardiolipin (aCL) antibody, the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus (SLICC/ACR-DI) score, duration of prednisone use, and cumulative prednisone dosage.

PATIENTS AND METHODS

Patients with SLE were enrolled from the outpatient clinic of the rheumatology division of the Universidade Federal de São Paulo/Escola Paulista de Medicina between September 1998 and September 2000.

The inclusion criteria were SLE classification according to ACR criteria,19–21 female sex, age 18–55 years, disease duration >5 years, and prednisone use for at least one year. Exclusion

Abbreviations: aCL, anticardiolipin; ACR, American College of Rheumatology; BMI, body mass index; CAD, coronary artery disease; CI, confidence interval; ECG, electrocardiography; HDL, high density lipoprotein; LDL, low density lipoprotein; MI, myocardial infarction; OR, odds ratio; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SPECT, single photon emission computed tomography.
criteria were contraindications for the dipyridamole protocol, current or previous acute MI, history of angina pectoris, coronary interventions (coronary catheterisation, coronary artery bypass surgery, or percutaneous transluminal coronary angioplasty), pregnancy, and nursing.

Blood and urine samples were obtained from the patients and the following laboratory tests carried out: glucose, cholesterol, triglyceride, blood cell count, anti dsDNA antibody, serum complement, ACL antibody, and urine analysis. Global disease activity was assessed by the SLEDAI score. All patients were examined and their clinical charts were reviewed to obtain clinical and serological data and to calculate the SLICC/ACR-DI score. Total cumulative dosage and duration of prednisone use were calculated in patients with SLE, followed up regularly at the rheumatology division with intervals between evaluations not exceeding four months since diagnosis.

Traditional CAD risk factors considered were arterial hypertension (blood pressure \(\geq 140\times 90\) mm Hg or use of antihypertensive drugs), diabetes mellitus (fasting glucose \(\geq 7.0\) mmol/l, use of insulin or oral hypoglycaemic agents), dyslipidaemia (high density lipoprotein (HDL) cholesterol \(<0.90\) mmol/l, low density lipoprotein (LDL) cholesterol \(\geq 3.35\) mmol/l, triglyceride level \(>2.26\) mmol/l), postmenopausal status, current smoking, obesity (body mass index (BMI) \(>30\) kg/m\(^2\)), and premature family CAD profile (definite acute MI or sudden death before age 55 in first degree male relatives and before age 65 in first degree female relatives). Myocardial perfusion scintigraphy was evaluated using single photon emission computed tomography (SPECT) with technetium-99m-sestamibi (99mTc-sestamibi) as radiotracer. A two phase, one day protocol was used, with images being captured at rest and after dipyridamole induced stress. After 12 lead electrocardiography (ECG) performed at rest, patients received 8 mCi of 99mTc-sestamibi (Cardiolite; Du Pont Merck Pharmaceutical, USA) given as an intravenous bolus. Myocardial images at rest were acquired after one hour. Two hours later, pharmacological cardiac stress was induced in patients with 0.56 mg/kg of dipyridamole (Persantin; Boehringer Ingelheim, Argentina) infused for four minutes. Myocardial images were acquired with patients in the supine position, 24 mCi of 99mTc-sestamibi was injected as an intravenous bolus. During and after pharmacological stress, heart rate, blood pressure, ECG results, and symptoms were monitored at one minute intervals. After one hour, SPECT images were again obtained. A cardiologist was in attendance to supervise the pharmacological stress test. The test was concluded prematurely according to the following conventional clinical criteria: 2nd or 3rd grade atrioventricular blockade, systolic hypotension \(<80\) mm Hg, ST segment fall \(\geq 2\) mm, angina pectoris, headache, hyperventilation, and/or gastrointestinal symptoms. Patients who had cardiac or vascular symptoms received 120 mg of aminophylline (Aminofilina; Novartis Biocieências, Brazil).

All patients were asked to abstain from smoking and alcoholic and caffeine products for 24 hours before the perfusion test. Drugs containing methylxanthine (aminophylline, pentoxifylline, and theophylline), calcium channel blockers, and \(\beta\) blockers were also stopped 48 hours before the procedure. ST segment alterations during or after dipyridamole infusion were considered significant if ST deviations were \(\geq 1\) mm compared with baseline ECG. If the ST segment was abnormal in the resting ECG, the result of the dipyridamole test was considered to be abnormal if any additional deviation was \(\geq 2\) mm.

A tomographic gammacamera (APEX SPX-4/4HR, Elscint, Israel) was used to acquire myocardial scintigraphy images. Data were acquired as 60 frames, 20 seconds per frame, according to the current conventional clinical protocol.

Resting 99mTc-sestamibi and stress induced myocardial perfusion images were reconstructed using routine clinical protocols. Perfusion images were displayed as short axis, vertical long axis, and horizontal long axis tomograms for assessment of perfusion defects. Three expert observers unaware of the patient’s clinical history and CAD risk factor profile performed the image analysis. The test was defined as normal if no regional hypoconcentration was found in two series evaluated. Abnormalities were considered to be reversible (suggestive of ischaemia) if they were found only after stress, and fixed (suggestive of fibrosis) if they were present both at rest and after stress.

The ethics committee of Universidade Federal de São Paulo/Escola Paulista de Medicina approved this study, and all patients signed an informed consent term before enrolment.

### Statistical analysis

The \(\chi^2\) test, \(\chi^2\) Pearson test, and Fisher test were used to analyse qualitative variables. The \(t\) test was used to analyse quantitative variables, and Spearman’s correlation was used to verify correlation between two variables. A logistic regression model was performed to evaluate the influence of different variables on myocardial perfusion abnormalities. A \(p\) value \(<0.05\) was considered significant and a \(p\) value between 0.05 and 0.10 was considered a tendency towards significance.

### RESULTS

Eighty two patients (59% were white), with a mean (SD) age of 37 (10) years and mean (SD) disease duration 127 (57) months, were studied. The mean (SD) age at the time of SLE diagnosis was 27 (9) years, with a median of 25 years.

The mean SLEDAI score was 6 (5) and the mean SLICC/ACR-DI score was 2 (2). Only four (5%) patients had four ACR criteria, seven (9%) had five criteria, 23 (28%) had six, 20 (24%) had seven, and 28 (34%) had eight or more criteria. The prevalence of different clinical and laboratory features (according to ACR criteria) was: malar rash in 90%, discoid rash in 23%, photosensitivity in 89%, oral ulcers in 37%, arthritis in 88%, serositis in 37%, renal disorder in 49%, neurological disorder in 11%, haemato logical disorder in 88%, immunological disorders in 82%, and antinuclear antibodies in 99%.

Seventy patients (85%) presented at least one CAD risk factor and 30 (37%) patients had at least three risk factors at the time of the study. Patients had a mean (SD) of 2.2 (1.6) traditional risk factors. A positive correlation was found between age and the number of CAD risk factors \((r_1 = 0.482)\). The most common CAD risk factors were arterial hypertension (40%), higher LDL cholesterol level (32%), current smoking (32%), and postmenopausal status (28%).

Myocardial perfusion abnormalities were found in 23 (28%) patients. Fifty six per cent of the total myocardial defects were reversible, 20% were fixed, and 24% were reversible and fixed defects. We found a tendency towards an association between the number of CAD risk factors and myocardial perfusion abnormalities \((p = 0.054)\).

A lower HDL cholesterol level was found in 10% of patients with normal scintigraphy and in 30% of patients with an abnormal test (odds ratio (OR) = 3.86, \(p = 0.04\)) (table 1). Total cholesterol, HDL cholesterol, LDL cholesterol, very low density lipoprotein (VLDL) cholesterol, triglyceride, and BMI were analysed in patients with normal and abnormal myocardial perfusion scintigraphy. The mean BMI of patients with perfusion defects was significantly higher than the mean BMI of patients with normal results \((28\,kg/m^2\times 24\,kg/m^2, \ p = 0.02)\). Excluding BMI, we did not find significant difference between patients with or without perfusion defects.
Subclinical heart disease has been reported to be an independent predictor of CAD risk in the general population. Women with subclinical disease were at greater risk for acute MI. Early investigation for CAD in the preclinical stage in young women with SLE is justified because cardiovascular events are an important cause of morbidity and mortality in this population. Published reports show that coronary disease (angina pectoris or acute MI) is more common in women with SLE than in the general population. Moreover, the mean age of patients with SLE who had coronary disease was younger than seen in the general population.

We studied patients with more than five years of SLE, who had used steroids for at least one year, in attempt to evaluate patients at a greater risk for CAD. We analysed only asymptomatic patients, because we wanted to investigate subclinical heart disease. We also excluded patients older than 55 years, because women after this age have higher risk for CAD than younger women in a general population.

Longer steroid use was associated with a poor outcome in three studies. A high steroid dose also seems to be associated with a poor prognosis in patients with SLE. Longer steroid treatment and greater cumulative prednisone dose showed a significant association with atherosclerotic plaque in carotid arteries. On the other hand, the duration of prednisone treatment may be related to the duration of SLE and higher prednisone use may be related to a more severe disease. We did not find significant difference in prednisone use, duration or cumulative steroid dosage between patients with SLE with normal or abnormal myocardial scintigraphy. Raham et al reported that the incidence of premature CAD in patients with SLE independent of steroid use was greater (4.5/1000) than that observed in the Framingham Heart Study (2.8/1000 women).

Our results were similar to those reported by Petri et al, who found at least one CAD risk factor in 97% of 225 patients evaluated. The most prevalent CAD risk factor was a sedentary life style (70%). Hypercholesterolaemia was found in 56%, arterial hypertension in 41%, family history of premature CAD in 41%, and obesity in 38%. They also found 33% of patients with at least three of these traditional risk factors.

In the current study, patients with abnormal scintigraphy had 2.6 (1.7) risk factors, showing the role of risk factors in the scintigraphy abnormality. Bruce et al found a mean of 1.8 (1.0) CAD risk factors in a series of patients with SLE, and Raham et al reported that patients with SLE and CAD had 2.0 (0.8) risk factors at the time of the cardiovascular event.

The frequency of myocardial perfusion abnormalities in our study was lower than that reported by Hosenpud et al (38%) and Bruce et al (40%). Hosenpud et al evaluated 26 patients younger than 50 years, irrespective of their previous cardiac history. Bruce et al evaluated 130 consecutive patients independent of CAD risk factors or coronary disease history and included older patients. On the other hand, Schillaci et al and Sun et al found a high proportion of asymptomatic patients with abnormal myocardial scintigraphy. Schillaci et al studied 28 young patients with SLE without CAD risk factors and without CAD symptoms, and reported 64% with abnormal scintigraphy. Sun et al studied 28 asymptomatic patients with SLE and observed 43% with an abnormal myocardial perfusion test. Most of the perfusion defects in our study were reversible, as also reported by Hosenpud et al and Bruce et al.

Considering the result of the myocardial perfusion study as a dependent variable, and current age, traditional CAD risk factors, and SLE related risk factors as independent variables, we performed logistic regression analysis using several models. Larger HDL cholesterol level and diabetes mellitus were the classic risk factors with most influence on the myocardial perfusion scintigraphy results. Bruce et al also had

<p>| Table 1 Association between CAD risk factors and myocardial perfusion scintigraphy in 82 patients with SLE |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|</p>
<table>
<thead>
<tr>
<th>CAD risk factors</th>
<th>Normal MIBI (n = 59) No (%)</th>
<th>Abnormal MIBI (n = 23) No (%)</th>
<th>p Value</th>
<th>OR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>20 (34)</td>
<td>13 (57)</td>
<td>0.06</td>
<td>2.53</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>2 (3)</td>
<td>3 (13)</td>
<td>0.13</td>
<td>4.27</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>6 (10)</td>
<td>7 (30)</td>
<td>0.04</td>
<td>3.86</td>
</tr>
<tr>
<td>LDL cholesterol =&gt; 3.55 mmol/l</td>
<td>20 (34)</td>
<td>6 (26)</td>
<td>0.50</td>
<td>0.69</td>
</tr>
<tr>
<td>Triglyceride =&gt; 2.26 mmol/l</td>
<td>12 (20)</td>
<td>4 (17)</td>
<td>1</td>
<td>1.21</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>16 (27)</td>
<td>7 (30)</td>
<td>0.76</td>
<td>1.18</td>
</tr>
<tr>
<td>Smoking</td>
<td>20 (34)</td>
<td>6 (26)</td>
<td>0.30</td>
<td>0.69</td>
</tr>
<tr>
<td>Obesity</td>
<td>9 (15)</td>
<td>7 (30)</td>
<td>0.13</td>
<td>1.18</td>
</tr>
<tr>
<td>CAD family history</td>
<td>8 (14)</td>
<td>4 (17)</td>
<td>0.73</td>
<td>0.74</td>
</tr>
</tbody>
</table>

*p<0.05; †x² test; ‡Fisher test.  
CAD, coronary artery disease; CI, confidence interval; MIBI, myocardial perfusion scintigraphy; OR, odds ratio.
noted that HDL cholesterol level was an important risk factor for myocardial perfusion abnormality. 60

Logistic regression analysis including SLE related coronary risk factors showed that current vasculitis was associated with myocardial perfusion abnormality, suggesting that the vascular inflammatory process may have a role in abnormal myocardial perfusion. We do not know if myocardial perfusion abnormalities represent the presence of atherosclerotic disease or just an endothelial dysfunction, an early stage of the atherosclerosis. To define the real cause of scintigraphic abnormalities it will be necessary to perform a coronary angiography in these patients. There are no reported studies showing that abnormal myocardial scintigraphy represents athero-sclerotic plaque. However, the significant association between lower HDL cholesterol level and abnormal scintigraphy strongly suggests that myocardial perfusion defects may represent an early atherosclerotic process. This study showed the important effects of traditional CAD risk factors and some SLE related coronary risk factors such as vasculitis on the results of myocardial scintigraphy. Lower HDL cholesterol level and diabetes mellitus were the variables associated with myocardial perfusion abnormalities in our patients. Actual vasculitis was the most important SLE related variable associated with abnormal myocardial perfusion.

Knowledge of the role of atherosclerosis in morbidity and mortality in patients with SLE shows the importance of recognising and controlling modifiable coronary risk factors even in asymptomatic young women with SLE.

ACKNOWLEDGEMENTS

We thank Gilberto Alonso and Marta M Sevillano, members of the nuclear medicine division of the Universidade Federal de São Paulo Escola Paulista de Medicina, who read the scintigraphy results. Financial support for the work: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP project 98/11794-6.

Authors’ affiliations

E M C Sella, E I Sato, Rheumatology Division, Universidade Federal de São Paulo, Escola Paulista de Medicina, Brazil
W A Leite, J A Oliveira Filho, Cardiology Division, Universidade Federal de São Paulo, Escola Paulista de Medicina, Brazil
A Barbieri, Image Department, Universidade Federal de São Paulo, Escola Paulista de Medicina, Brazil

REFERENCES


44. American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging)/American Society of Nuclear Cardiology. Guidelines for clinical use of cardiac radionuclide imaging. J Am Coll Cardiol 1995;25:521-47.


